Encompass Health (EHC) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $1.55
- EPS estimate
- $1.48
- EPS surprise
- +4.77%
- Revenue surprise
- +1.66%
- Revenue
- $1.6B
- Revenue estimate
- $1.6B
- Reported
- Aug 5, 2026
Encompass Health reported Q2 2026 results on August 5, 2026. Earnings per share were $1.55, ahead of the $1.48 estimate by 4.77%. Revenue was $1.6 billion, 1.66% above the consensus. Compared with Q2 2025, EPS rose about 11% from $1.40, and revenue was up from $1.5 billion.
The table shows steady growth since late 2022. Quarterly revenue was $1.3 billion through Q2 2022, fell to $1.1 billion in Q3 2022, and has since climbed to $1.6 billion in each of the last two quarters. Q3 2022 was also the EPS low in the table, at $0.67. Annual EPS rose from $3.41 in 2022 to $3.64 in 2023, $4.43 in 2024 and $5.46 in 2025, about 23% more in the last year. Q1 2026 holds the EPS high, at $1.60. The first half of 2026 adds up to $3.15 per share, about 14% more than the same half of 2025. Encompass Health beat the EPS estimate in 17 of the 20 quarters shown, including 16 in a row since Q3 2022.
Q3 results came out between October 26 and October 29 in each of the past five years. That points to late October 2026 for the next report.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $1.48 | $1.55 | +4.77% | $1.6B | SEC |
| Q1 2026 | Apr 30, 2026 | $1.49 | $1.60 | +7.09% | $1.6B | SEC |
| Q4 2025 | Feb 5, 2026 | $1.30 | $1.46 | +12.14% | $1.5B | SEC |
| Q3 2025 | Oct 29, 2025 | $1.20 | $1.23 | +2.54% | $1.5B | SEC |
| Q2 2025 | Aug 4, 2025 | $1.23 | $1.40 | +14.13% | $1.5B | SEC |
| Q1 2025 | Apr 24, 2025 | $1.19 | $1.37 | +15.36% | $1.5B | SEC |
| Q4 2024 | Feb 6, 2025 | $1.02 | $1.17 | +14.16% | $1.4B | SEC |
| Q3 2024 | Oct 28, 2024 | $0.94 | $1.03 | +9.33% | $1.4B | SEC |
| Q2 2024 | Aug 5, 2024 | $1.01 | $1.11 | +9.69% | $1.3B | SEC |
| Q1 2024 | Apr 24, 2024 | $0.94 | $1.12 | +19.49% | $1.3B | SEC |
| Q4 2023 | Feb 7, 2024 | $0.82 | $0.95 | +16.41% | $1.2B | SEC |
| Q3 2023 | Oct 26, 2023 | $0.78 | $0.86 | +9.68% | $1.2B | SEC |
| Q2 2023 | Aug 1, 2023 | $0.74 | $0.95 | +28.00% | $1.2B | SEC |
| Q1 2023 | Apr 27, 2023 | $0.70 | $0.88 | +24.88% | $1.2B | SEC |
| Q4 2022 | Feb 7, 2023 | $0.83 | $0.88 | +5.85% | $1.1B | SEC |
| Q3 2022 | Oct 26, 2022 | $0.64 | $0.67 | +5.05% | $1.1B | SEC |
| Q2 2022 | Aug 1, 2022 | $0.97 | $0.89 | −7.81% | $1.3B | SEC |
| Q1 2022 | Apr 27, 2022 | $0.91 | $0.97 | +6.25% | $1.3B | SEC |
| Q4 2021 | Feb 1, 2022 | $1.05 | $0.97 | −7.58% | $1.3B | SEC |
| Q3 2021 | Oct 27, 2021 | $1.06 | $1.03 | −2.84% | $1.3B | SEC |
Quarterly revenue
Frequently asked questions
When did Encompass Health (EHC) last report earnings?
Encompass Health last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did EHC beat earnings estimates?
Yes. Encompass Health reported EPS of $1.55 for Q2 2026 against a $1.48 estimate — a 4.77% beat.
How much revenue did EHC report last quarter?
Encompass Health reported $1.6B in revenue for Q2 2026, against a consensus estimate of $1.6B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.